We are live on ! Find out more
BLTE icon

Belite Bio

80 hedge funds and large institutions have $1.44B invested in Belite Bio in 2026 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 22

24% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 17

23% more capital inflows, than outflows

Capital inflows: $284M | Capital outflows: $232M

5% more funds holding

Funds holding: 76 → 80 (+4)

0.46% more ownership

Funds ownership: 23.18% → 23.63% (+0.46%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
80
Holders Change
+4
Holders Change %
+5.26%
% of All Funds
0.95%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
21
Increased
28
Reduced
22
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BLTE Hedge Fund Activity: Q2 2026 in Review

80 of the 8,401 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q2 2026, worth a combined $1.44B — up 1.3% from $1.42B a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new BLTE positions and 17 closed out — a net gain of 4 holders — while 28 added to existing stakes and 22 trimmed.

The largest buyer was Maverick Capital, opening a new position worth an estimated $60.7M. The largest seller was UBS Group, cutting an estimated $83.3M.

  • 80 institutional investors held Belite Bio (BLTE) as of Q2 2026, up from 76 in Q1 2026.
  • Funds reported $1.44B of Belite Bio stock for Q2 2026, up 1.3% quarter-over-quarter.
  • 21 funds opened new Belite Bio positions in Q2 2026 and 17 closed out, a net change of +4 holders.
  • The largest Belite Bio buyer in Q2 2026 was Maverick Capital, an estimated $60.7M added.
  • The largest Belite Bio seller in Q2 2026 was UBS Group, an estimated $83.3M sold.

Based on aggregated 13F filings for Q2 2026.